Fig. 2: DNA content abnormality as a predictive marker of persistent/recurrent HGD/IMC or EAC. | Modern Pathology

Fig. 2: DNA content abnormality as a predictive marker of persistent/recurrent HGD/IMC or EAC.

From: Persistent or recurrent Barrett’s neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue

Fig. 2

A–C This patient underwent EMR for HGD in November 2012 (A), which showed a distinct aneuploid population in the DNA histogram (red, B). The patient was found to have persistent HGD in January 2013 (C), which was removed by another EMR and two courses of RFA. The subsequent biopsies showed no evidence of neoplasia within 3 years. D–F Another patient underwent EMR of a nodular lesion in February 2016. The EMR demonstrated HGD (D) with normal DNA content in the DNA histogram (E). The follow-up biopsies showed no evidence of neoplasia within 4 years (F).

Back to article page